Article
Deleting the β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth.
Journal of hepatology - 1 Aug 2022
Loesch Robin, Caruso Stefano, Paradis Valérie, Godard Cecile, Gougelet Angélique, Renault Gilles, Picard Simon, Tanaka Ingrid, Renoux-Martin Yoan, Perret Christine, Taketo Makoto Mark, Zucman-Rossi Jessica, Colnot Sabine
Abstract excerpt
BACKGROUND & AIMS: One-third of hepatocellular carcinomas (HCCs) harbor mutations activating the β-catenin pathway, predominantly via mutations in the CTNNB1 gene itself. Mouse models of Apc loss-of-function are widely used to mimic β-catenin-dependent tumorigenesis. Given the low prevalence of APC mutations in human HCCs, we aimed to generate liver tumors through CTNNB1 exon 3 deletion (βcatΔex3). We then...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.